Plasma exchange treatment for CNS inflammatory demyelinating disease

Multiple Sclerosis Therapeutics, Fourth Edition

Volumn , Issue , 2011, Pages 454-464

  Weinshenker, Brian G ^a   Keegan, B Mark ^b   Winters, Jefrey L ^a   Nakashima, Ichiro ^c   Fujihara, Kazuo ^c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927072589     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139023986.042     Document Type: Chapter

References (76)

1. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010;25:83-177.
2. Tindall RS, Walker JE, Ehle AL, et al. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 1982;32:739-43.
3. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308: 173-80.
4. Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985;35:312-19.
5. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143-9.
6. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86.
7. Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009;73:949-53.
8. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991;337:441-6.
9. Ramunni A, De Robertis F, Brescia P, et al. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis. her Apher Dial 2008;12:250-4.
10. Moldenhauer A, Haas J, Wascher C, et al. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest 2005;35: 523-30.
11. Schneidewind JM, Winkler R, Ramlow W, et al. Immunoadsorption-a new therapeutic possibility for multiple sclerosis? Transfusion Science 1998;19 Suppl:59-63.
12. Schmitt E, von Appen K, Behm E. Immunoadsorption with phenylalanine-immobilized polyvinyl alcohol versus plasma exchange - a controlled pilot study in multiple sclerosis. herapeutic Plasmapheresis 1993;12:239-42.
13. Schmitt E, Behm E, Buddenhagen F, et al. Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis-first results of a double blind controlled trial. Prog Clin Biol Res 1990;337:289-92.
14. Hosokawa S, Oyamaguchi A, Yoshida O. Successful immunoadsorption with membrane plasmapheresis for multiple sclerosis. ASAIO Trans 1989;35: 576-7.
15. Palm M, Behm E, Schmitt E, et al. Immunoadsorption and plasma exchange in multiple sclerosis: complement and plasma protein behaviour. Biomat ArtifCells Immobilization Biotechnol 1991;19: 283-96.
16. Weinshenker B. Therapeutic plasma exchange for multiple sclerosis. In Rudick R, Goodkin D, eds. Multiple Sclerosis: Experimental and Applied Therapeutics. London: Martin Dunitz, 1999:323-33.
17. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143-9.
18. Weinshenker B, O'Brien P, Petterson T, et al. A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease. Ann Neurol 1999;46:878-86.
19. Meca-Lallana JE, Rodríguez-Hilario H, Martínez-Vidal S, et al. Plasmapheresis: Its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study. Revista Neurologia 2003;37:917-26.
20. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis - treatment of 10 patients. Neurology 2004;63:1081-3.
21. Bennetto L, Totham A, Healy P, et al. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system - A report of six cases. J Neurol 2004;251:1515-21.
22. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-6.
23. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009;72:402-9.
24. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009;361:1075-80.
25. Vamvakas EC, Pineda AA, Weinshenker BG. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. J Clin Apher 1995;10:163-70.
26. Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985;35:312-19.
27. Noseworthy JH, Vandervoort MK, Penman M, et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991;337:1540-1.
28. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308: 173-80.
29. Gordon PA, Carroll DJ, Etches WS, et al. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci 1985;12:39-44.
30. Tindall RS, Walker JE, Ehle AL, et al. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 1982;32:739-43.
31. Trouillas P, Neuschwander P, Nighoghossian N, et al. [Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years] Immunosuppression intensive dans la sclerose en plaques progressive. Etude ouverte comparant trois groupes: cyclophosphamide, cyclophosphamide-plasmaphereses et temoins. Resultats a trois ans. Rev Neurol 1989;145:369-77.
32. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
33. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-12.
34. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis ofNMO: a study on antibody titre. Brain 2007;130:1235-43.
35. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15.
36. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61.
37. Misu T, Fujihara K, Nakamura M, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006;209:269-75.
38. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194-205.
39. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130: 1224-34.
40. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-32.
41. Bonnan M, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009;15:487-92.
42. Ohashi T, Ota K, Shimizu Y, et al. Immunoadsorption plasma pheresis for the treatment of neuromyelitis optica spectrum disorder. Mult Scler 2008;14: S170-S170.
43. Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. her Apher Dial 2009;13:505-8.
44. Kanter DS, Horensky D, Sperling RA, et al. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 1995;45:824-7.
45. Lin CH, Jeng JS, Yip PK. Plasmapheresis in acute disseminated encephalomyelitis. J Clin Apher 2004;19:154-9.
46. Stricker RB, Miller R, Kiprov DD. Role of plasmapheresis in acute disseminated (postinfectious) encephalomyelitis. J Clin Apher 1992;7:173-9.
47. Khurana DS, Melvin JJ, Kothare SV, et al. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005;116:431-6.
48. Berger T, Reindl M. Biomarkers in multiple sclerosis: role of antibodies. Disease Markers 2006;22: 207-12.
49. Weinshenker BG, Wingerchuk DM, Pittock SJ, et al. NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers 2006;22:197-206.
50. Goto H, Matsuo H, Nakane S, et al. Plasmapheresis affects T Thelper type-1/T Thelper type-2 balance of circulating peripheral lymphocytes. her Apher 2001;5:494-6.
51. Racke MK. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 2008;21 Suppl 1:S9-18.
52. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. NEngl J Med 2008;358:676-88.
53. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010;67:452-61.
54. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-82.
55. Zettl UK, Hartung HP, Pahnke A, et al. Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology 2006;67: 1515-16.
56. Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-16.
57. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:1-11.
58. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: passive transfer to rats byhuman immunoglobulin. Biochem Biophys Res Commun 2009;386:623-7.
59. Kinoshita M, Nakatsuji Y, Moriya M, et al. Astrocytic necrosis is induced by anti-aquap orin-4 antib o dy-po sitive serum. Neuroreport 2009;20:508-12.
60. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617-29.
61. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-43.
62. Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128:988-1002.
63. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009;73:1628-37.
64. Basic-Jukic N, Kes P, Glavas-Boras S, et al. Complications of therapeutic plasma exchange: experience with 4857 treatments. her ApherDial 2005; 9:391-5.
65. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apher 1994; 9:1-5.
66. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher 2007;22:270-6.
67. Klingel R, Fassbender C, Fassbender T, et al. Rheopheresis: rheologic, functional, and structural aspects. her Apher 2000;4:348-57.
68. Yeh J-H, Chen W-H, Chiu H-C. Complications of double-filtration plasmapheresis. Transfusion 2004; 44:1621-5.
69. Moldenhauer A, Haas J, Wascher C, et al. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest 2005;35:523-30.
70. Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-herasorb). Br J Haematol 2001;112:91-7.
71. Huestis DW, Morrison FS. Adverse clinical effects of immune sorption with staphylococcal protein A columns. Transfus Med Rev 1996;10:62-70.
72. Noseworthy JH, Shumak KH, Vandervoort MK. Long-term use of antecubital veins for plasma exchange. The Canadian Cooperative Multiple Sclerosis Study Group. Transfusion 1989;29:610-13.
73. Bambauer R, Schneidewind-Muller J-M, Schiel R, et al. Side-effects and complications in large-bore catheters for apheresis. her Apher Dial 2003; 7:221-4.
74. Lhote F, Guillevin L, Leon A, et al. Complications of plasma exchange in the treatment of polyarteritis nodosa and Churg-Strauss angiitis and the contribution of adjuvant immunosuppressive therapy: a randomized trial in 72 patients. Artificial Organs 1988;12:27-33.
75. Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998;41:414-20.
76. Wing EJ, Bruns FJ, Fraley DS, et al. Infectious complications with plasmapheresis in rapidlyprogressive glomerulonephritis. J Am Med Assoc 1980;244:2423-6.